Analytical Method Development and Validation for Elagolix and its Related Substances: A Comprehensive Review
Keywords:
Elagolix sodium, related substances, stability-indicating method, RP-HPLC, UHPLC, forced degradation, quality by design, ICH Q2(R2)Abstract
Elagolix sodium is the first orally active, non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist, approved by the US FDA in 2018 for moderate to severe endometriosis-associated pain (Orilissa® tablets, 150 and 200 mg) and later in combination with estradiol and norethindrone acetate for heavy menstrual bleeding due to uterine fibroids (Oriahnn® capsules). Its uracil core carries a secondary-amine, butanoic-acid side chain, a chiral centre and hindered biaryl rotation, which together give a varied impurity profile of process intermediates, the S-enantiomer, atropisomers, oxidative and cyclised (δ-lactam) degradants, potential N-nitroso derivatives and alkyl-phosphate genotoxic impurities.
This review surveys the analytical methods published for elagolix between 2020 and 2026. It covers RP-HPLC assay methods, stability-indicating related-substances methods by HPLC and UHPLC, chiral and atropisomer separations, LC-MS/MS methods for genotoxic impurities and plasma, structural elucidation of degradation products, spectrofluorimetric methods, and a method for the fixed-dose combination. For each, the chromatographic conditions, validation findings and limitations are summarised.
Although several related-substances methods now exist, they disagree on degradation behaviour (alkaline lability), use long runs (46–75 min) or extreme pH, rarely quantify identified degradants against reference standards, and none is pharmacopoeial or validated under ICH Q2(R2)/Q14. N-nitroso elagolix and atropisomer control remain largely unaddressed. A strategy for a robust, MS-compatible, stability-indicating method is proposed.
Published
How to Cite
Issue
Section
Copyright (c) 2026 Futuristic Publications

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.